NASSCOM Recognizes Zifo Lab Data AI Tool
Oct 16, 2026
Analyst and Vendor Research
IDC Names ZS a Leader in Life Sciences Evidence Services
Sep 20, 2026
ZS was named a Leader in a 2026 IDC MarketScape assessment of life sciences research and development services for real world data and evidence.
ZS said in a press release that it was named a Leader in a 2026 IDC MarketScape assessment. The report evaluates life sciences research and development providers offering real world data, evidence platforms, technology and consulting services.
The assessment cited the company's Medical and Evidence practice, ZAIDYN Medical platform, Patient Radar platform, ZS Data Nexus and Evidence Pro. ZS reported a 90% net promoter score and 97% client retention for its real world data and evidence work.
ZS said it has delivered more than 250 integrated evidence plans. The company also said its process increased output from one plan completed in four to five months to more than 30 plans completed in 10 weeks.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 10 Dimer Health's AI-supported post-discharge team found unmet care needs in 23% of 680 hospital patients Nov 10 Google.org gives Clalit $2 million for a multilingual voice AI that books care for 5 million members Nov 10 Elomia Health acquires Earkick, an AI wellbeing companion used by more than 250,000 people Nov 10 XpertDox brings autonomous AI medical coding to Camarena Health's Central Valley clinics Nov 9 Palantir lobbied a UK health minister to extend its NHS AI platform to GP records, messages showFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Zensar says AI influenced deals reached 36% of Q2 FY27 orders
Nov 02, 2026
Enterprise
Infotech Launches CIO Analytics and Acquires Zluri
Oct 14, 2026
Acquisitions
EDDA Technology Named to TIME HealthTech List for Second Year
Oct 14, 2026
Analyst and Vendor Research
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Oct 12, 2026
Biotech
AstraZeneca and Oracle Partner on AI for Clinical Trials
Oct 20, 2026
Healthcare
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.